Dr. Stanley Myers Featured in Portland Magazine
HIFU for Prostate Cancer A Cutting-Edge, Non-Invasive Treatment with Low Risk of Side Effects While prostate cancer is a fairly common disease among men in the United States, with about […]… read more
HIFU for Prostate Cancer A Cutting-Edge, Non-Invasive Treatment with Low Risk of Side Effects While prostate cancer is a fairly common disease among men in the United States, with about […]… read more
When you’re first given a diagnosis of having prostate cancer, it can feel like you alone bear the burden. But it’s important to remember that you are not alone, and […]… read more
Since HIFU was approved for prostate tissue ablation and our company was founded, our network of physicians in the US have treated 1,000 patients. It only seems appropriate that this […]… read more
Prostate cancer support groups can help men navigate a prostate cancer diagnosis, treatment and recovery. And while we know men aren’t the first people to raise their hand and say […]… read more
Prostate cancer treatment options fall into a spectrum of least aggressive to most aggressive when it comes to how to treat the disease. There are a lot of different kinds […]… read more
Prostate cancer research is important in order for scientists and clinicians to discover new ways to manage the disease in which normal cells in a man’s prostate gland change and […]… read more
HIFU Prostate Services, LLC, the leading provider of HIFU technology to physician practices in the United States, was founded in 2015 and since then has grown rapidly to now offer […]… read more
In honor of September being prostate cancer awareness month, we are going to feature topics about prostate cancer, treatments, survivors and awareness initiatives all month long. It’s important to keep […]… read more
HIFU Prostate Services, the largest provider of HIFU Services in US is pleased to announce an Extensive Multicenter Research Study that Demonstrates Sonablate® Focal HIFU Outcomes are Equivalent to Surgery […]… read more
Source: EUROPEAN UROLOGY, June 27, 2018 https://doi.org/10.1016/j.eururo.2018.06.006 Background: Clinically significant nonmetastatic prostate cancer (PCa) is currently treated using whole-gland therapy. This approach is effective but can have urinary, sexual, and […]… read more